Karen P Best1, Thomas Sullivan2, Debra Palmer3, Michael Gold4, Declan John Kennedy5, James Martin6, Maria Makrides7. 1. Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; Women's & Children's Health Research Institute, Discipline of Paediatrics, School of Medicine, and karen.best@adelaide.edu.au. 2. School of Population Health, University of Adelaide, Adelaide, South Australia, Australia; 3. Women's & Children's Health Research Institute, School of Paediatrics and Child Health, University of Western Australia, Subiaco, Western Australia, Australia; and. 4. Discipline of Paediatrics, School of Medicine, and. 5. Discipline of Paediatrics, School of Medicine, and Department of Respiratory and Sleep Medicine, Women's & Children's Hospital, North Adelaide, South Australia, Australia. 6. Department of Respiratory and Sleep Medicine, Women's & Children's Hospital, North Adelaide, South Australia, Australia. 7. Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; Women's & Children's Health Research Institute, Discipline of Paediatrics, School of Medicine, and.
Abstract
BACKGROUND AND OBJECTIVE: Evidence from randomized controlled trials in early infancy suggest that prenatal supplementation with Ω-3 (n-3) long-chain polyunsaturated fatty acids (LCPUFA) reduces the incidence of allergic disease characterized by an immunoglobulin E (IgE) response. We aimed to determine whether protective effects were evident in the 6-year-old offspring of women supplemented withn-3 rich fish oil during pregnancy. METHODS:Six-year follow-up of children (n = 706) with a family history of allergic disease from theDocosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. Women were randomly allocated to receive n-3 LCPUFA-rich fish oil capsules (800 mg/d docosahexaenoic acid DHA and 100mg/d eicosapentaenoic acid) or vegetable oil capsules (without n-3 LCPUFA). Allergic disease symptoms including eczema, wheeze, rhinitis, and rhino-conjunctivitis, were assessed using the International Study of Asthma and Allergies in Childhood questionnaire and sensitization to allergens was measured by skin prick test. RESULTS: There was no difference in the percentage of children with any IgE-associated allergic disease between the n-3 LCPUFA and control groups (116/367 [31.5%] vs 106/336 [31.5%]; adjusted relative risk, 1.04; 95% confidence interval, 0.82-1.33; P = .73). There was a reduction in the percentage of children sensitized to house dust mite Dermatophagoides farinae (49/367 [13.4%] vs 68/336 [20.3%]; adjusted relative risk, 0.67, 95% confidence interval, 0.44-1.00; P = .0495). CONCLUSIONS:Prenatal n-3 LCPUFA supplementation did not reduce IgE-associated allergic disease at 6 years of age. Secondary outcomes were suggestive of a protective effect of the intervention on the incidence of D. farinae sensitization.
RCT Entities:
BACKGROUND AND OBJECTIVE: Evidence from randomized controlled trials in early infancy suggest that prenatal supplementation with Ω-3 (n-3) long-chain polyunsaturated fatty acids (LCPUFA) reduces the incidence of allergic disease characterized by an immunoglobulin E (IgE) response. We aimed to determine whether protective effects were evident in the 6-year-old offspring of women supplemented with n-3 rich fish oil during pregnancy. METHODS: Six-year follow-up of children (n = 706) with a family history of allergic disease from the Docosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. Women were randomly allocated to receive n-3 LCPUFA-rich fish oil capsules (800 mg/d docosahexaenoic acidDHA and 100mg/d eicosapentaenoic acid) or vegetable oil capsules (without n-3 LCPUFA). Allergic disease symptoms including eczema, wheeze, rhinitis, and rhino-conjunctivitis, were assessed using the International Study of Asthma and Allergies in Childhood questionnaire and sensitization to allergens was measured by skin prick test. RESULTS: There was no difference in the percentage of children with any IgE-associated allergic disease between the n-3 LCPUFA and control groups (116/367 [31.5%] vs 106/336 [31.5%]; adjusted relative risk, 1.04; 95% confidence interval, 0.82-1.33; P = .73). There was a reduction in the percentage of children sensitized to house dust mite Dermatophagoides farinae (49/367 [13.4%] vs 68/336 [20.3%]; adjusted relative risk, 0.67, 95% confidence interval, 0.44-1.00; P = .0495). CONCLUSIONS: Prenatal n-3 LCPUFA supplementation did not reduce IgE-associated allergic disease at 6 years of age. Secondary outcomes were suggestive of a protective effect of the intervention on the incidence of D. farinae sensitization.
Authors: Ekaterina Maslova; Sheryl L Rifas-Shiman; Emily Oken; Thomas A E Platts-Mills; Diane R Gold Journal: Ann Allergy Asthma Immunol Date: 2018-09-12 Impact factor: 6.347
Authors: Nikos Stratakis; Theano Roumeliotaki; Emily Oken; Ferran Ballester; Henrique Barros; Mikel Basterrechea; Sylvaine Cordier; Renate de Groot; Herman T den Dekker; Liesbeth Duijts; Merete Eggesbø; Maria Pia Fantini; Francesco Forastiere; Ulrike Gehring; Marij Gielen; Davide Gori; Eva Govarts; Hazel M Inskip; Nina Iszatt; Maria Jansen; Cecily Kelleher; John Mehegan; Carolina Moltó-Puigmartí; Monique Mommers; Andreia Oliveira; Sjurdur F Olsen; Fabienne Pelé; Costanza Pizzi; Daniela Porta; Lorenzo Richiardi; Sheryl L Rifas-Shiman; Sian M Robinson; Greet Schoeters; Marin Strøm; Jordi Sunyer; Carel Thijs; Martine Vrijheid; Tanja G M Vrijkotte; Alet H Wijga; Manolis Kogevinas; Maurice P Zeegers; Leda Chatzi Journal: Int J Epidemiol Date: 2017-10-01 Impact factor: 7.196
Authors: Carina Venter; Carlo Agostoni; S Hasan Arshad; Miriam Ben-Abdallah; George Du Toit; David M Fleischer; Matthew Greenhawt; Deborah H Glueck; Marion Groetch; Nonhlanhla Lunjani; Kate Maslin; Alexander Maiorella; Rosan Meyer; Muraro Antonella; Merryn J Netting; Bright Ibeabughichi Nwaru; Debra J Palmer; Micheala P Palumbo; Graham Roberts; Caroline Roduit; Pete Smith; Eva Untersmayr; Lauren A Vanderlinden; Liam O'Mahony Journal: Pediatr Allergy Immunol Date: 2020-08-06 Impact factor: 5.464
Authors: K P Best; T R Sullivan; D J Palmer; M Gold; J Martin; D Kennedy; M Makrides Journal: World Allergy Organ J Date: 2018-06-15 Impact factor: 4.084